A detailed history of Cm Management, LLC transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Cm Management, LLC holds 500,000 shares of HRTX stock, worth $560,000. This represents 0.84% of its overall portfolio holdings.

Number of Shares
500,000
Previous 300,000 66.67%
Holding current value
$560,000
Previous $1.05 Million 5.24%
% of portfolio
0.84%
Previous 0.97%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.73 - $3.67 $346,000 - $734,000
200,000 Added 66.67%
500,000 $995,000
Q1 2024

May 14, 2024

SELL
$1.71 - $3.06 $42,750 - $76,500
-25,000 Reduced 7.69%
300,000 $831,000
Q4 2023

Feb 12, 2024

SELL
$0.54 - $1.82 $67,500 - $227,500
-125,000 Reduced 27.78%
325,000 $552,000
Q3 2023

Nov 07, 2023

SELL
$0.97 - $1.8 $48,500 - $90,000
-50,000 Reduced 10.0%
450,000 $463,000
Q2 2023

Aug 04, 2023

BUY
$1.11 - $2.88 $166,500 - $432,000
150,000 Added 42.86%
500,000 $580,000
Q1 2023

May 08, 2023

BUY
$1.51 - $3.25 $151,000 - $325,000
100,000 Added 40.0%
350,000 $529,000
Q4 2022

Feb 09, 2023

SELL
$2.25 - $4.67 $56,250 - $116,750
-25,000 Reduced 9.09%
250,000 $625,000
Q3 2022

Nov 04, 2022

BUY
$2.66 - $5.37 $199,500 - $402,750
75,000 Added 37.5%
275,000 $1.16 Million
Q1 2022

May 09, 2022

BUY
$4.63 - $9.94 $694,500 - $1.49 Million
150,000 Added 300.0%
200,000 $1.14 Million
Q4 2021

Feb 02, 2022

SELL
$8.35 - $12.6 $83,500 - $126,000
-10,000 Reduced 16.67%
50,000 $457,000
Q3 2021

Nov 08, 2021

BUY
$10.13 - $15.0 $101,300 - $150,000
10,000 Added 20.0%
60,000 $641,000
Q1 2021

May 12, 2021

BUY
$14.49 - $20.72 $507,150 - $725,200
35,000 Added 233.33%
50,000 $811,000
Q4 2020

Feb 04, 2021

BUY
$14.61 - $22.14 $219,150 - $332,100
15,000 New
15,000 $317,000

Others Institutions Holding HRTX

About HERON THERAPEUTICS, INC.


  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $133M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track This Portfolio

Track Cm Management, LLC Portfolio

Follow Cm Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cm Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cm Management, LLC with notifications on news.